Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Olivier Rixe"'
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Timothy F. Cloughesy, Andrew B. Lassman, Ray Li, Annick Desjardins, Shilpa Alekar, Carrie T. Taylor, David A. Reardon, Olivier Rixe, Jason H. Williams
Publikováno v:
Investigational new drugs. 38(6)
Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy i
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Autor:
Olivier Rixe, F. Meiring Nortier, Mehran Makvandi, Sam Simon, Jonathan W. Engle, Jeffrey P. Norenberg, Robert W. Atcher, Michael E. Fassbender, Edouard Dupis, Kevin D. John, Eva R. Birnbaum
Publikováno v:
Targeted Oncology. 13:189-203
Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nan
Autor:
Solmaz Sahebajam, Adam B. Cohen, Varun Monga, Mohammed Milham, Surasak Phuphanich, Jeremy Rudnick, Olivier Rixe, Christopher Smith, Eugene P. Kennedy, Rimas V. Lukas, Howard Colman
Publikováno v:
Neuro Oncol
BACKGROUND Optimal management of progressive high-grade gliomas (HGG) is not fully defined and outcomes are poor. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme which converts tryptophan to kynurenines, which contribute to the immunosuppresive tum
Autor:
Vinay K. Puduvalli, Edouard Dupis, Marc C. Mabray, Audra A. Kerwin, Karen S. SantaCruz, Trisha Wise-Draper, John L. Villano, Olivier Rixe, John C. Morris, Angela N. Johnson, Karen Cline-Parhamovich
BACKGROUND: Ependymomas are rare primary nervous system tumors accounting for about 3% of adult brain tumors in the United States. The current standard of care includes surgical resection and radiation therapy, with more than half experiencing relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a355eb04e3bbfda6d8cdf9f6d79625
https://europepmc.org/articles/PMC6217694/
https://europepmc.org/articles/PMC6217694/
Autor:
Olivier Rixe, Jose Otero, Vinay K. Puduvalli, Angela N. Johnson, John C. Morris, Trisha Wise-Draper, Pierre Giglio, John L. Villano
BACKGROUND: Saposin C-dioleylphosphatidylserine (SapC-DOPS) is a novel blood-brain barrier penetrant nanoliposomal agent that targets externalized phosphatidylserine overexpressed on tumor cell membranes. A recent Phase 1a BXQ-350 trial (NCT02859857)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f0d8f0c40a7ad7d109fdcdb76b8ee6
https://europepmc.org/articles/PMC6217345/
https://europepmc.org/articles/PMC6217345/
Autor:
Alain C. Mita, David Martin Darst, Michael A. Postow, Angela Jain, Celia Andreu, Robert Wasserman, Robert Busby, Gerald Steven Falchook, Igor Puzanov, Erika Hamilton, Michael Szarek, Tomislav Dragovich, Narayan Lebaka, Eric K. Rowinsky, Rebecca Redman, Monica M. Mita, Masoud Tavazoie, Shubham Pant, Isabel Kurth, Olivier Rixe, Syed Ahsan Raza, Russell J. Schilder, Kevin B. Kim, R. Donald Harvey, Foster C. Gonsalves, Emerson A. Lim, James Strauss, Bartosz Chmielowski
Publikováno v:
Cancer Research. 80:CT146-CT146
Background: RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. Binding of ApoE to its receptor LRP8 robustly inhibits angiogenesis and depletes myeloid derived suppressor cells (MDS
Autor:
Anthony J. Olszanski, Olivier Rixe, Olugbenga Olowokure, Séverine Doroumian, John C. Morris, Jian Y. Yin, Roger B. Cohen, Liji Shen, Igor Puzanov, Patricia LoRusso
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Publikováno v:
Expert Opinion on Drug Discovery. 10:925-935
Introduction: Based on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). Axitinib is one o